<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39350892</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1592-9558</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of burns and fire disasters</Title><ISOAbbreviation>Ann Burns Fire Disasters</ISOAbbreviation></Journal><ArticleTitle>AN OUTBREAK OF EXTENSIVELY DRUG-RESISTANT <i>ACINETOBACTER BAUMANNII</i> IN A BELGIAN TERTIARY BURN WOUND CENTER.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>225</EndPage><MedlinePgn>217-225</MedlinePgn></Pagination><Abstract><AbstractText>The burn intensive care unit (ICU) of the Queen Astrid Military Hospital experienced an outbreak with an extensively drug-resistant <i>Acinetobacter baumannii</i> (XDR-Ab) strain, which began when all burn wound patients from all over Belgium were sent there as part of the national COVID-19 action plan. The purpose of this study is to report on the investigation and strategies that were implemented to contain the outbreak. Between October 2020 and May 2021, five of the 72 patients admitted to the ICU met the acute outbreak case definition (attack rate 7%). Their median age was 46 years and their median total body surface area burned was 39%. All patients developed at least one XDR-Ab infection, with in total three pulmonary, three bloodstream and five burn wound infections. One patient died. All XDR-Ab isolates were only susceptible to colistin. Whole genome sequencing of the isolates from the first two patients revealed an identical <i>A. baumannii</i> ST2 genotype, suggesting an outbreak. XDR-Ab-positive patients were cohorted with dedicated staff. The infection control team intensified its training on hand hygiene, excreta management and bio-cleaning procedures. Concurrently, 30 environmental samples were collected, which proved negative for XDR-Ab. Spatio-temporal associations were found for all XDR-Ab-positive patients, suggesting cross-transmission via staff's hands. We describe an XDR-Ab outbreak in a burn ICU over a seven-month period, in a context of increased workload. This series underlines the importance of a correct staff-to-patient ratio, especially in outbreak situations.</AbstractText><CopyrightInformation>© 2024 Euro-Mediterranean Council for Burns and Fire Disasters.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costescu Strachinaru</LastName><ForeName>D I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Centre for Infectious Diseases, Queen Astrid Military Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallez</LastName><ForeName>J-L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Queen Astrid Military Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verroken</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Cliniques Universitaires Saint-Luc - Universite Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagemans</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Gene Technology, Department of Biosystems, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lood</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Gene Technology, Department of Biosystems, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vos</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirnay</LastName><ForeName>J-P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavigne</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Gene Technology, Department of Biosystems, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Burn Wound Centre, Queen Astrid Military Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strachinaru</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thorax Centre, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanbrabant</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Infectious Diseases, Queen Astrid Military Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soentjens</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Infectious Diseases, Queen Astrid Military Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Ann Burns Fire Disasters</MedlineTA><NlmUniqueID>101251186</NlmUniqueID><ISSNLinking>1592-9558</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="fre"><AbstractText>L’unité de soins intensifs (USI) pour brûlés de l’Hôpital Militaire Reine Astrid a connu une épidémie avec une souche d’<i>Acinetobacter baumannii</i> extrêmement résistante aux antibiotiques (XDR-Ab), qui a commencé pendant la période où tous les patients brûlés de Belgique y étaient référés à la suite du plan national COVID-19. Le but de cette étude est de décrire l’enquête épidémiologique et les stratégies utilisées pour contenir l’épidémie. Entre octobre 2020 et mai 2021, cinq des 72 patients admis à l’USI ont répondu à la définition de cas (taux d’attaque 7%). L’âge médian était de 46 ans, la surface corporelle brûlée médiane de 39%. Tous les patients ont développé au moins une infection par XDR-Ab : trois pneumonies, trois bactériémies et cinq infections de brûlures. Un patient est décédé. Tous les isolats XDR-Ab n’étaient sensibles qu’à la colistine. Le séquençage du génome entier des isolats des deux premiers patients a révélé un génotype identique d’A. <i>baumannii</i> ST2, suggérant une épidémie. Les patients XDR-Ab positifs ont été cohortés avec du personnel dédié. L’équipe d’hygiène hospitalière a intensifié sa formation sur l’hygiène des mains, la gestion des excréta et les procédures de bio-nettoyage. Simultanément, 30 échantillons environnementaux ont été collectés, qui étaient négatifs pour XDR-Ab. Des liens spatio-temporels ont été trouvés pour tous les patients XDR-Ab positifs, suggérant une transmission croisée manuportée. Nous décrivons une épidémie de XDR-Ab dans une USI pour brûlés sur une période de sept mois, dans un contexte de charge de travail accrue. Cette série souligne l’importance d’un ratio personnel-patients approprié, en particulier dans les situations d’épidémie.</AbstractText><CopyrightInformation>© 2024 Euro-Mediterranean Council for Burns and Fire Disasters.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acinetobacter baumannii</Keyword><Keyword MajorTopicYN="N">burn</Keyword><Keyword MajorTopicYN="N">hospital-acquired infection</Keyword><Keyword MajorTopicYN="N">intensive care unit</Keyword><Keyword MajorTopicYN="N">outbreak</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39350892</ArticleId><ArticleId IdType="pmc">PMC11372271</ArticleId><ArticleId IdType="pii">abfd-2024-03-217</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, et al. : Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev, 30(1): 409-447, 2017. doi: 10.1128/CMR.00058-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5217799</ArticleId><ArticleId IdType="pubmed">27974412</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayabali AF, Nguyen KC, Shwed PS, Crosthwait J, et al. : Comparison of the virulence potential of Acinetobacter strains from clinical and environmental sources. PLoS One, 7(5): e37024, 2012. doi: 10.1371/journal.pone.0037024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3360037</ArticleId><ArticleId IdType="pubmed">22655033</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Atrouni A, Joly-Guillou ML, Hamze M, Kempf M: Reservoirs of non-baumannii Acinetobacter species. Front Microbiol, 7: 49, 2016. doi: 10.3389/fmicb.2016.00049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740782</ArticleId><ArticleId IdType="pubmed">26870013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendt C, Dietze B, Dietz E, Rüden H: Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol, 35(6): 1394-7, 1997. doi: 10.1128/jcm.35.6.1394-1397.1997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC229756</ArticleId><ArticleId IdType="pubmed">9163451</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawad A, Heritage J, Snelling AM, Gascoyne-Binzi DM, et al. : Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces. J Clin Microbiol, 34: 2881-7, 1996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC229427</ArticleId><ArticleId IdType="pubmed">8940416</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsan M, Klompas M: Acinetobacter baumannii: an emerging and important pathogen. J Clin Outcomes Manag, 17(8): 363-369, 2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782967</ArticleId><ArticleId IdType="pubmed">26966345</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassetti M, Labate L, Russo C, Vena A, et al. : Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective. Expert Opin Pharmacother, 22(2): 167-177, 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">32915685</ArticleId></ArticleIdList></Reference><Reference><Citation>Valcek A, Nesporova K, Whiteway C, De Pooter T, et al. : Genomic analysis of a strain collection containing multidrug-, extensively drug-, pandrug-, and carbapenem-resistant modern clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother, 66(9): e0089222, 2022. doi: 10.1128/aac.00892-22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9487538</ArticleId><ArticleId IdType="pubmed">35969073</ArticleId></ArticleIdList></Reference><Reference><Citation>Playford EG, Craig JC, Iredell JR: Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect, 65: 204-11, 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17254667</ArticleId></ArticleIdList></Reference><Reference><Citation>Manchanda V, Sanchaita S, Singh N: Multidrug resistant acinetobacter. J Glob Infect Dis, 2(3): 291-304, 2010. doi: 10.4103/0974777X.68538</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946687</ArticleId><ArticleId IdType="pubmed">20927292</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System : Overview of nosocomial infections caused by Gramnegative bacilli. Clin Infect Dis, 41(6): 848-54, 2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">16107985</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KA, Moran KA, McAllister CK, Gray PJ: Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis, 11(8): 1218-24, 2005. doi: 10.3201/1108.050103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3320488</ArticleId><ArticleId IdType="pubmed">16102310</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott P, Deye G, Srinivasan A, Murray C, et al. : An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis, 44(12): 1577-84, 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17516401</ArticleId></ArticleIdList></Reference><Reference><Citation>Chusri S, Chongsuvivatwong V, Rivera JI, Silpapojakul K, et al. : Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii. Antimicrob Agents Chemother, 58(7): 4172-9, 2014. doi: 10.1128/AAC.02992-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4068534</ArticleId><ArticleId IdType="pubmed">24820079</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernards AT, Harinck HI, Dijkshoorn L, van der Reijden TJ, et al. : Persistent Acinetobacter baumannii? Look inside your medical equipment. Infect Control Hosp Epidemiol, 25: 1002-4, 2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15566039</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis LL, Cosgrove SE, Song X, Kim D, et al. : An outbreak of multidrug-resistant Acinetobacter baumannii associated with pulsatile lavage wound treatment. JAMA, 292: 3006-11, 2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15613669</ArticleId></ArticleIdList></Reference><Reference><Citation>Das I, Lambert P, Hill D, Noy M, et al. : Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units. J Hosp Infect, 50: 110-4, 2002.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846537</ArticleId></ArticleIdList></Reference><Reference><Citation>Villegas MV, Hartstein AI: Acinetobacter outbreaks, 1977–2000. Infect Control Hosp Epidemiol, 24: 284-95, 2003.</Citation><ArticleIdList><ArticleId IdType="pubmed">12725359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilks M, Wilson A, Warwick S, Price E, et al. : Control of an outbreak of multidrug-resistant Acinetobacter baumannii—calcoaceticus colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation. Infect Control Hosp Epidemiol, 27: 654-8, 2006.</Citation><ArticleIdList><ArticleId IdType="pubmed">16807837</ArticleId></ArticleIdList></Reference><Reference><Citation>Denton M, Wilcox MH, Parnell P, Green D, et al. : Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit. Intensive Crit Care Nurs, 21: 94-8, 2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">15778073</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong G, Duse A, Richards G, Marais E: Back to basics - optimizing the use of available resources during an outbreak of multidrug resistant Acinetobacter spp. J Hosp Infect, 57: 186-7, 2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15183255</ArticleId></ArticleIdList></Reference><Reference><Citation>Podnos YD, Cinat ME, Wilson SE, Cooke J, et al. : Eradication of multi-drug resistant Acinetobacter from an intensive care unit. Surg Infect (Larchmt), 2: 297-301, 2001.</Citation><ArticleIdList><ArticleId IdType="pubmed">12593705</ArticleId></ArticleIdList></Reference><Reference><Citation>Aygun G, Demirkiran O, Utku T, Mete B, et al. : Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect, 52: 259-62, 2002.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473469</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanetti G, Blanc DS, Federli I, Raffoul W, et al. : Importation of Acinetobacter baumannii into a burn unit: a recurrent outbreak of infection associated with widespread environmental contamination. Infect Control Hosp Epidemiol, 28: 723-5, 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17520548</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2013 guidelines: http://www.socinorte.com/wp-content/uploads/2013/03/Criterios-de-IN-2013.pdf. Accessed 25th July 2022.</Citation></Reference><Reference><Citation>EUCAST version 2019: https://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/. Accessed 25th July 2022.</Citation></Reference><Reference><Citation>Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, et al. : Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, 18(3): 268-281, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">21793988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lood C, Peeters C, Lamy-Besnier Q, Wagemans J, et al. : Genomics of an endemic cystic fibrosis Burkholderia multivorans strain reveals low within-patient evolution but high between-patient diversity. PLoS Pathog, 17(3): e1009418, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7993779</ArticleId><ArticleId IdType="pubmed">33720991</ArticleId></ArticleIdList></Reference><Reference><Citation>Seemann T: Snippy: fast bacterial variant calling from NGS reads. https://github.com/tseemann/snippy. Accessed 22nd August 2022.</Citation></Reference><Reference><Citation>Seemann T: 2016. ABRicate: mass screening of contigs for antibiotic resistance genes. https://github.com/tseemann/abricate. Accessed 22nd August 2022.</Citation></Reference><Reference><Citation>Arndt D, Grant JR, Marcu A, Sajed T, et al. : PHASTER: a better, faster version of the PHAST phage search tool. Nucleic Acids Res, 44(W1): W16-21, 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987931</ArticleId><ArticleId IdType="pubmed">27141966</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertelli C, Laird MR, Williams KP, Simon Fraser University Research Computing Group et al. : IslandViewer 4: expanded prediction of genomic islands for larger-scale datasets. Nucleic Acids Res, 45(W1): W30-W35, 2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570257</ArticleId><ArticleId IdType="pubmed">28472413</ArticleId></ArticleIdList></Reference><Reference><Citation>Florensa AF, Kaas RS, Clausen PTLC, Aytan-Aktug D, et al. : Res-Finder - an open online resource for identification of antimicrobial resistance genes in next-generation sequencing data and prediction of phenotypes from genotypes. Microb Genom, 8(1): 000748, 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8914360</ArticleId><ArticleId IdType="pubmed">35072601</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.ncbi.nlm.nih.gov/refseq. Accessed 28th August 2022.</Citation></Reference><Reference><Citation>Jolley KA, Bray JE, Maiden MCJ: Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res, 3: 124, 2018. doi: 10.12688/wellcomeopenres.14826.1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192448</ArticleId><ArticleId IdType="pubmed">30345391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostyanev T, Xavier BB, García-Castillo M, Lammens C, et al. : Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study. Int J Antimicrob Agents, 57(6): 106345, 2021. doi: 10.1016/j.ijantimicag.2021.106345.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887390</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Popolo A, Giannouli M, Triassi M, Brisse S, et al. : Molecular epidemiological investigation of multidrug-resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clin Microbiol Infect, 17(2): 197-201, 2011. doi: 10.1111/j.1469-0691.2010.03254.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">20456455</ArticleId></ArticleIdList></Reference><Reference><Citation>Société Française D’hygiène Hospitalière Recommandations Nationales Prévention de La Transmission Croisée: Précautions Complémentaires Contact: https://www.sf2h.net/publications/prevention-de-transmission-croisee-precautions-complementaires-contact. Accessed 26th July 2022.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. U.S. Department of Health and Human Services: Antibiotic resistant threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf [Google Scholar]. Accessed 30th July 2022.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. U.S. Department of Health and Human Services: Interim guidance for a public health response to contain novel or targeted multidrug-resistant organisms (MDROs), 2019. https://www.cdc.gov/hai/containment/guidelines.html [Google Scholar]. Accessed 30th July 2022.</Citation></Reference><Reference><Citation>Maragakis LL, Perl TM: Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis, 46(8): 1254-63, 2008. doi: 10.1086/529198.</Citation><ArticleIdList><ArticleId IdType="pubmed">18444865</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos D, Pirnay JP, Bilocq F, Jennes S, et al. : Molecular epidemiology and clinical impact of acinetobacter calcoaceticus-baumannii complex in a Belgian burn wound center. PLoS One, 11(5): e0156237, 2016. doi: 10.1371/journal.pone.0156237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4880317</ArticleId><ArticleId IdType="pubmed">27223476</ArticleId></ArticleIdList></Reference><Reference><Citation>Risser C, Pottecher J, Launoy A, Ursenbach A, et al. : Management of a major carbapenem-resistant Acinetobacter baumannii outbreak in a French intensive care unit while maintaining its capacity unaltered. Microorganisms, 10(4): 720, 2022. doi: 10.3390/microorganisms10040720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9031073</ArticleId><ArticleId IdType="pubmed">35456771</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>